Premium Nahrungsergänzungsmittel | artgerecht

Genotypic Resistance Testing – Explanation & Use

Genotypic resistance testing is a molecular diagnostic method that analyses genetic mutations in pathogens to detect drug resistance early and guide targeted treatment decisions.

Regular tips about health Regular tips about health

Things worth knowing about "Genotypic resistance testing"

Genotypic resistance testing is a molecular diagnostic method that analyses genetic mutations in pathogens to detect drug resistance early and guide targeted treatment decisions.

What is genotypic resistance testing?

Genotypic resistance testing is a diagnostic procedure in which the genetic material (genotype) of a pathogen – such as a virus, bacterium, or fungus – is analysed for specific genetic changes (mutations). These mutations can render the pathogen insensitive (resistant) to certain medications. By identifying such resistance mutations early, therapy can be adjusted in a targeted manner before treatment failure occurs.

The method is used primarily in the treatment of HIV, hepatitis B and C, tuberculosis, and other infectious diseases. It has become an indispensable tool in modern infectiology and personalised medicine.

How does genotypic resistance testing work?

A sample is taken from the patient – usually blood, cerebrospinal fluid, or tissue – and the genetic material of the pathogen is extracted. This material is then analysed using molecular biology techniques. The key methods include:

Sequencing (e.g. Sanger sequencing or Next-Generation Sequencing, NGS): The complete genome or specific regions of the pathogen are decoded and screened for known resistance mutations.
Polymerase Chain Reaction (PCR): Specific DNA or RNA segments are amplified to detect resistance genes.
Hybridisation assays: Known mutations are directly identified using specific gene probes.

The resulting sequence data are compared against databases of known resistance mutations to generate a clinically relevant interpretation of the expected sensitivity or resistance to specific medications.

Areas of application

HIV therapy

In HIV treatment, genotypic resistance testing is a standard component of diagnostics. Because HIV has a high mutation rate, it can rapidly develop resistance mutations under antiretroviral therapy (ART). Testing helps to select effective drug combinations and prevent treatment failure. Current guidelines recommend testing at the time of diagnosis and upon treatment failure.

Hepatitis B and C

In the management of hepatitis B and hepatitis C, genotypic resistance testing may be required, particularly when prior treatment has occurred or treatment failure is evident. For hepatitis C, the viral genotype is additionally determined, as it substantially influences the choice of antiviral therapy.

Tuberculosis and other bacterial infections

In tuberculosis (TB), genotypic testing enables the rapid detection of resistance to first-line antibiotics such as rifampicin and isoniazid. This is of particular clinical importance in multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), where early results can significantly accelerate appropriate treatment.

Oncology

In cancer medicine, genotypic resistance testing is used to detect mutations in tumour cells that cause resistance to targeted therapies or chemotherapy agents. This allows treatment to be individually optimised for each patient.

Advantages of genotypic resistance testing

Speed: Results are often available within a few days, considerably faster than phenotypic tests.
Sensitivity: Resistance mutations can be detected even in small pathogen populations (minority variants).
Standardisation: Molecular biology methods are well standardised and reproducible.
No culture required: Growing the pathogen in a laboratory is not necessary, which is particularly advantageous for slow-growing organisms such as mycobacteria.

Limitations and disadvantages

Known mutations only: Only previously identified resistance mutations can be detected. Novel, previously unknown mutations remain undetected.
Interpretation: The clinical significance of some mutations is not always clear and requires specialist expertise.
Pathogen concentration: Testing may fail if the pathogen load in the sample is very low.
Cost: More advanced sequencing methods (NGS) in particular are cost-intensive.

Difference from phenotypic resistance testing

In contrast to the genotypic approach, phenotypic resistance testing examines the actual growth behaviour of the pathogen in the presence of a drug (e.g. minimum inhibitory concentration, MIC). While phenotypic testing more directly measures the functional outcome of resistance, genotypic testing delivers results more quickly and provides deeper insight into the molecular causes. In clinical practice, both methods are often used in a complementary manner.

References

World Health Organization (WHO): Guidelines for Surveillance of Drug Resistance in Tuberculosis, 5th Edition, WHO Press, Geneva, 2015.
European AIDS Clinical Society (EACS): EACS Guidelines Version 12.0, 2023. Available at: https://www.eacsociety.org/guidelines/eacs-guidelines/
Zignol M et al.: "Fluoroquinolone resistance in Mycobacterium tuberculosis: emerging threat and management challenges". Clinical Infectious Diseases, 2016. PubMed PMID: 27371674.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category